Nomination Committee for Vimian’s 2024 Annual General Meeting

Regulatory press release
Nov 06 2023

Nomination Committee for Vimian’s 2024 Annual General Meeting

The Nomination Committee for Vimian Group has been appointed.

Vimian’s Nomination Committee for the 2024 Annual General Meeting has been appointed based on the ownership structure as of September 30, 2023.

The Nomination Committee comprises the following members:

Håkan Håkansson, Fidelio Capital

Suzanne Sandler, Handelsbanken Fonder

Nick Bova, Finn Pharmaceuticals Trust

Gabriel Fitzgerald, Chairman of the Board

Chairman of the Nomination Committee will be appointed at the Nomination Committee’s first meeting.

The Annual General Meeting of Vimian Group will be held on 22 May 2024. Shareholders who would like to submit proposals to the Nomination Committee for the 2024 Annual General Meeting can submit such via email to generalmeetings@vimian.com no later than 29 March, 2024.

About Vimian

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market’s most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 15,000 veterinary clinics and 1,700 labs, sells to over 90 markets, has 1,000 employees and annual revenues of approximately EUR 280 million. For more information, please visit: www.vimian.com. FNCA Sweden AB is appointed the Company’s Certified Adviser.